Compare Citius Pharmaceuticals Inc (CTXR) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Otis Worldwide Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Otis Worldwide Corp trades at $65.95 (market cap $25.17B). The key difference: Otis Worldwide Corp is far larger — about 1848× Citius Pharmaceuticals Inc's market cap, and Otis Worldwide Corp pays a 2.66% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Otis Worldwide Corp for 66 Days on average.
| CTXR | OTIS | |
|---|---|---|
Market Cap | $13.62M | $25.17B |
Volume | 132,438 | 4,542,442 |
Sector | Health | Industrials |
52-Week High | $1.82 | $93.62 |
52-Week Low | $0.48 | $64.05 |
Typical Hold Time | 17 Days | 66 Days |
Enterprise Value | $3.79M | $33.20B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% in the last session, with a bearish technical signal from moving averages but bullish oscillators. The company reported $7.1M revenue for the first nine months of fiscal 2026 from LYMPHIR sales, yet net losses persist, with a net income margin of -651.27%. Cash flow remains positive due to financing activities, and analyst consensus is strongly bullish with five buy ratings.
The outlook hinges on commercial execution of LYMPHIR, offering growth potential amid high losses. Key risks include sustained negative profitability, cash burn, and competitive pressures. Investors should weigh the speculative growth narrative against fundamental weaknesses.
Otis Worldwide trades at $66.11, up 0.56% today but near its 52-week low, with a bearish technical signal and mixed earnings history. The company reported revenue of $14.43B in 2025 with a net income margin of 10.17%, though recent quarters have seen EPS misses. Analyst consensus is split between Buy and Hold, with a price target of $87.00. News highlights margin pressures from China and labor costs, alongside CEO succession plans for 2027.
The outlook is cautious due to near-term margin headwinds and weak equipment demand, but the service segment's growth and dominant market position offer long-term stability. Risks include China exposure and cost inflation, while institutional buying and a discounted valuation present potential upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
